Market capitalization | $182.92m |
Enterprise Value | $-18.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.14 |
EV/Sales (TTM) EV/Sales | -1.62 |
P/S ratio (TTM) P/S ratio | 15.93 |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue growth (TTM) Revenue growth | -66.85% |
Revenue (TTM) Revenue | $11.48m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
9 Analysts have issued a Caribou Biosciences forecast:
9 Analysts have issued a Caribou Biosciences forecast:
Sep '24 |
+/-
%
|
||
Revenue | 11 11 |
67%
67%
|
|
Gross Profit | 6.76 6.76 |
77%
77%
|
|
EBITDA | -160 -160 |
54%
54%
|
EBIT (Operating Income) EBIT | -165 -165 |
51%
51%
|
Net Profit | -148 -148 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Head office | United States |
CEO | Rachel Haurwitz |
Employees | 158 |
Founded | 2011 |
Website | www.cariboubio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.